Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year.
Speaking on the company’s second-quarter (fiscal year 2022) earnings call, Chairman & CEO Geoff Martha said Medtronic expects its MiniMed 780G insulin pump system with the Guardian 4 sensor for continuous glucose monitoring (CGM) to drive growth once approved, with the company currently in talks with the FDA.
Get the full story at our sister site, Drug Delivery Business News.